Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Seif Al Abri, Ministry of Health Oman
  • ,
  • Thereza Kasaeva, World Health Organization
  • ,
  • Giovanni Battista Migliori, Istituti Clinici Scientifici Maugeri IRCCS
  • ,
  • Delia Goletti, L. Spallanzani IRCCS, ESCMID Study Group on Mycobacteria
  • ,
  • Dominik Zenner, IOM
  • ,
  • Justin Denholm, Royal Melbourne Hospital
  • ,
  • Amal Al Maani, The Royal Hospital
  • ,
  • Daniela Maria Cirillo, IRCCS San Raffaele Scientific Institute
  • ,
  • Thomas Schön, Linköping University
  • ,
  • Troels Lillebæk, Kobenhavns Universitet
  • ,
  • Amina Al-Jardani, Ministry of Health Oman
  • ,
  • Un Yeong Go, International Tuberculosis Research Centre
  • ,
  • Hannah Monica Dias, World Health Organization
  • ,
  • Simon Tiberi, Barts Health NHS Trust, Queen Mary University of London
  • ,
  • Fatma Al Yaquobi, Ministry of Health Oman
  • ,
  • Faryal Ali Khamis, The Royal Hospital
  • ,
  • Padmamohan Kurup, Muscat Governorate
  • ,
  • Michael Wilson, Zero TB Initiative
  • ,
  • Ziad Memish, Alfaisal University, Emory University
  • ,
  • Ali Al Maqbali, Disease Surveillance and Control
  • ,
  • Muhammad Akhtar, WHO MENA Region TB Programme
  • ,
  • Christian Wejse
  • Eskild Petersen

Aim: The purpose of this viewpoint is to summarize the advantages and constraints of the tools and strategies available for reducing the annual incidence of tuberculosis (TB) by implementing the World Health Organization (WHO) End TB Strategy and the linked WHO TB Elimination Framework, with special reference to Oman. Methods: The case-study was built based on the presentations and discussions at an international workshop on TB elimination in low incidence countries organized by the Ministry of Health, Oman, which took place from September 5 to September 7, 2019, and supported by the WHO and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Results: Existing tools were reviewed, including the screening of migrants for latent TB infection (LTBI) with interferon-gamma release assays, clinical examination for active pulmonary TB (APTB) including chest X-rays, organization of laboratory services, and the existing centres for mandatory health examination of pre-arrival or arriving migrants, including examination for APTB. The need for public–private partnerships to handle the burden of screening arriving migrants for active TB was discussed at length and different models for financing were reviewed. Conclusions: In a country with a high proportion of migrants from high endemic countries, screening for LTBI is of high priority. Molecular typing and the development of public–private partnerships are needed.

OriginalsprogEngelsk
TidsskriftInternational Journal of Infectious Diseases
Vol/bind92
Sider (fra-til)S60-S68
Antal sider9
ISSN1201-9712
DOI
StatusUdgivet - 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 183163377